The one-year mortality rate is 3-4%; stage 3 – decompensated stage, with ascites, the one-year mortality rate is 20%; stage 4 – decompensated stage, with rupture and bleeding of the esophagogastric fundic varices, the one-year mortality rate is 57%; stage 5 –severe decompensated stage with infection and renal dysfunction, the one-year mortality rate can reach 67%. 6.1 Assessment of liver function and its compensatory capacity Liver biochemical indicators Elevated serum enzymatic indicators such as ALT and AST in liver biochemical indicators do not reflect specific functional impairment or disorders of the liver, but only serve as markers indicating liver injury and reflect the degree of hepatocellular damage. Significant abnormalities in bilirubin levels, prothrombin time (PT) and prothrombin activity (PTA), albumin and cholinesterase in biochemical indicators usually reflect impaired or impaired partial functions of the liver, such as excretory function and synthetic function. 6.2 Assessment of liver reserve function Child-Pugh grading is a commonly used tool to assess liver reserve function. The scoring method is simple and easy to use and reflects the severity of the disease. The 1-year survival rates of Child-Pugh grades A, B and C in patients with cirrhosis are 100%, 80% and 45%, respectively. It is important to note that serum albumin levels play an important role in the scoring system. 6.3 Evaluation of complications The formation of portal hypertension is an important cause for the emergence of complications such as ruptured esophagogastric variceal bleeding, ascites, hepatic encephalopathy and hepatorenal syndrome. portal pressure gradient is an effective means of diagnosing portal hypertension, but its invasive nature limits the use of HVPG in clinical practice. HVPG has a good correlation with LSM, and when LSM ≥ 13.6 kPa The accuracy and specificity of LSM in diagnosing portal hypertension were 97% and 92%, respectively. The diagnosis of esophagogastric varices still relies on gastroscopy. 6.4 Assessment of prognosis HCC is one of the common clinical regressions of cirrhosis. Baseline HBV DNA >1×104 copies/ml is the strongest independent predictor of HCC occurrence, therefore patients with cirrhosis, especially hepatitis B cirrhosis, should be screened regularly for HCC, and routine screening can be performed with serum alpha-fetoprotein (AFP) and liver ultrasound. The progression of chronic liver disease to decompensated cirrhosis often indicates a poor prognosis, and the model of end-stage liver disease (MELD) can effectively predict the risk of death from end-stage liver disease, and hyponatremia is an independent predictor of death from cirrhosis.